Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis, and Forecast (2025 – 2031)

Vaccine Adjuvants Market Size
The global vaccine adjuvants market size was valued at $4.06 billion in 2025 and is projected to reach $5.92 billion by 2031, growing at a CAGR of 6.5% during the forecast period.

Vaccine Adjuvants Market Overview
Vaccine adjuvants are substances added to vaccines to enhance and modulate the immune response to specific antigens, thereby improving the vaccine's overall efficacy. By stimulating immune cells and promoting the production of antibodies, adjuvants help ensure a stronger and more durable immune response, which is particularly beneficial for vulnerable populations such as the elderly or immunocom promised individuals. 
Companies can benefit from this growing focus on adjuvants by developing novel formulations that require fewer antigens per dose, ultimately reducing production costs and increasing vaccine availability. Additionally, advancements in adjuvant technologies allow for more targeted and efficient vaccine strategies, which can lead to increased market opportunities and partnerships with public health agencies. 

Vaccine Adjuvants Market Dynamics
The vaccine adjuvants market is expected to witness significant growth in the future due to the increasing prevalence of infectious diseases and cancer, growing demand for enhanced vaccine efficacy and durability, and expansion of global vaccination programs and initiatives. However, the high costs associated with developing and manufacturing adjuvants, limited awareness about the benefits of adjuvants among healthcare providers, and potential safety concerns related to certain adjuvant formulations are restraining the growth of the market.

Furthermore, development of novel adjuvant technologies, such as nanoparticle-based adjuvants, increasing focus on personalized medicine and targeted therapies, and collaboration between pharmaceutical companies, academic institutions, and government agencies for research.are the key trends propelling the vaccine adjuvants market. 

Increasing Prevalence of Infectious Diseases and Canceris Driving the Vaccine Adjuvants Market
The increasing prevalence of infectious diseases and cancer is significantly impacting the vaccine adjuvants market, by driving demand for more effective vaccines. 
• For example, the World Health Organization (WHO) reported that tuberculosis was the 13th leading cause of death worldwide in 2021, with approximately 1.6 million deaths, which has intensified the need for effective vaccination strategies. 
• Similarly, Dynavax Technologies entered into collaboration with the U.S. Department of Defense in October 2021 to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018, showcasing the critical role of adjuvants in addressing public health threats. 
The market is projected to grow significantly, with an estimated value of $1.2 billion by 2028, driven by rising funding and initiatives aimed at combating infectious diseases and enhancing vaccine efficacy.

By Product Type, the Adjuvant Emulsions Segment is projected to be the Largest Segment in the Vaccine Adjuvants Market
Adjuvant Emulsions is the largest segment in the vaccine adjuvants market, driven by their ability to enhance immune responses and improve vaccine efficacy against infectious diseases. 
• A notable example is the COVAXIN COVID-19 vaccine, which utilizes the novel adjuvant Alhydroxiquim-II, developed with funding from the National Institutes of Health (NIH). This adjuvant has been instrumental in making COVAXIN one of the most effective vaccines, with over 25 million doses administered globally as of 2022. 
• The collaboration between Bharat Biotech and ViroVax LLC highlights how innovative emulsions can enhance vaccine performance; Alhydroxiquim-II activates crucial immune receptors (TLR7 and TLR8), boosting the body’s response to the vaccine. 
This growth reflects a broader recognition of the critical role that adjuvants play in enhancing vaccine effectiveness, particularly as new pathogens emerge.

By Geography, North America Holds the Largest Share in the Market Revenue
North America holds the largest share of the vaccine adjuvants market, driven by increasing prevalence of infectious diseases and a heightened focus on vaccine efficacy. The Centers for Disease Control and Prevention (CDC) has reported rising cases of diseases such as influenza and HPV, prompting the need for effective vaccination strategies. 
• For instance, in August 2022, GSK acquired Affinivax, a company specializing in advanced pneumococcal vaccines that utilize innovative adjuvants to enhance immune responses. 
• Additionally, Croda International entered into partnerships in May 2023 with Amyris and Botanical Solutions to develop sustainable vaccine adjuvants, showcasing a commitment to improving vaccine formulations. 
• Furthermore, in January 2021, U.S. government has also launched initiatives like the HPV VAX NOW campaign to increase vaccination rates among young adults, further driving demand for effective adjuvants. 

Key Target Audience:
• Vaccine Adjuvant Manufacturers
• Vaccine Manufacturers
• Biotechnology and Biopharmaceutical Companies
• Academic and Research Institutions
• Regulatory Bodies and Government Agencies

List of the Key Players Profiled in the Report Includes:
• Dynavax Technologies 
• GSK plc
• Croda International plc
• Seppic
• Novavax  
• SPI Pharma 
• Agenus Inc
• Phibro Animal Health Corporation
• Aurorium
• Merck KGaA 
• Hawaii Biotech Inc.
• CSL Limited 

Recent Developments:
• In April 2025, GSK introduced a new prefilled syringe presentation for Shingrix, its adjuvanted vaccine for the prevention of shingles (herpes zoster) in adults. This new format aims to streamline vaccine preparation and administration, reducing complexity for healthcare providers and minimizing potential dosing errors. The updated version still includes GSK’s proprietary AS01 adjuvant, which enhances the immune response, especially in older adults.
• In July 2024, Seppic launched a new adjuvant platform designed for use in COVID-19 vaccines and other infectious disease applications, emphasizing enhanced immune responses.
• In August 2024, Novavax announced that its combination COVID-19 and flu vaccine candidate is progressing through clinical trials, utilizing an innovative adjuvant to boost immune responses.
• In June 2024, SPI Pharma introduced a new adjuvant formulation designed for use in pediatric vaccines, aiming to improve immunogenicity and safety profiles.

Market Segmentation:
The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments:

Market by, Product Type: 
• Adjuvant Emulsions
• Pathogen Components
• Particulate Adjuvants
• Saponin-based Adjuvants
• Other Product Types
 
Market by, Route of Administration:
• Intramuscular
• Oral Route 
• Subcutaneous
• Other Route of Administrations

Market by, Disease Type: 
• Cancer 
• Infectious Diseases
• OtherDisease Types

Market by, Application:
• Commercial Application
• Research Application

Market by, End User:
• Pharmaceutical Companies
• Research Institutions
• Contract Manufacturing Organizations

Market by, Geography:
The vaccine adjuvants market report also analyzes the major geographic regions and countries of the market. The regions and countries covered in the study include:
• North America (The United States, Canada, Mexico), Market Estimates, Forecast & Opportunity Analysis
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Market Estimates, Forecast & Opportunity Analysis
• Asia Pacific (China, Japan, India, South Korea, Australia, New Zealand, Rest of Asia Pacific), Market Estimates, Forecast & Opportunity Analysis
• South America (Brazil, Argentina, Chile, Rest of South America), Market Estimates, Forecast & Opportunity Analysis
• Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, Rest of Middle East & Africa), Market Estimates, Forecast & Opportunity Analysis

The report offers insights into the following aspects:
• Analysis of major market trends, factors driving, restraining, threatening, and providing opportunities for the market.
• Analysis of the market structure by identifying various segments and sub-segments of the market.
• Understand the revenue forecast of the market for North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
• Analysis of opportunities by identification of high-growth segments/revenue pockets in the market.
• Understand major player profiles in the market and analyze their business strategies.
• Understand competitive developments such as joint ventures, alliances, mergers and acquisitions, and new product launches in the market.

Table Of Content

1 Market Introduction             
    1.1 Market Definition         
    1.2 Research Scope and Segmentation         
    1.3 Stakeholders         
    1.4 List of Abbreviations         
              
2 Executive Summary             
              
3 Research Methodology             
    3.1 Identification of Data         
    3.2 Data Analysis         
    3.3 Verification         
    3.4 Data Sources         
    3.5 Assumptions         
              
4 Market Dynamics             
    4.1 Market Drivers         
    4.2 Market Restraints         
    4.3 Market Opportunities         
    4.4 Market Challenges         
              
5 Porter's Five Force Analysis             
    5.1 Bargaining Power of Suppliers         
    5.2 Bargaining Power of Buyers         
    5.3 Threat of New Entrants         
    5.4 Threat of Substitutes         
    5.5 Competitive Rivalry in the Market         
              
6 Global Vaccine Adjuvants Market by, Product Type             
    6.1 Overview         
    6.2 Adjuvant Emulsions         
    6.3 Pathogen Components         
    6.4 Particulate Adjuvants         
    6.5 Saponin-based Adjuvants         
    6.6 Other Product Types         
              
7 Global Vaccine Adjuvants Market by, Route of Administration             
    7.1 Overview         
    7.2 Intramuscular         
    7.3 Oral Route         
    7.4 Subcutaneous         
    7.5 Other Route of Administrations         
              
8 Global Vaccine Adjuvants Market by, Disease Type             
    8.1 Overview         
    8.2 Cancer         
    8.3 Infectious Diseases         
    8.4 Other Disease Types         
              
9 Global Vaccine Adjuvants Market by, Application             
    9.1 Overview         
    9.2 Commercial Application         
    9.3 Research Application         
              
10 Global Vaccine Adjuvants Market by, End User             
    10.1 Overview         
    10.2 Pharmaceutical Companies         
    10.3 Research Institutions         
    10.4 Contract Manufacturing Organizations         
              
11 Global Vaccine Adjuvants Market by, Geography             
    11.1 Overview         
    11.2 North America         
             11.2.1 US
             11.2.2 Canada
             11.2.3 Mexico
    11.3 Europe         
             11.3.1 Germany
             11.3.2 France
             11.3.3 UK
             11.3.4 Italy
             11.3.5 Spain
             11.3.6 Rest of Europe
    11.4 Asia Pacific         
             11.4.1 China
             11.4.2 Japan
             11.4.3 India
             11.4.4 South Korea
             11.4.5 Australia
             11.4.6 New Zealand
             11.4.7 Rest of Asia Pacific
    11.5 South America         
             11.5.1 Brazil
             11.5.2 Argentina
             11.5.3 Chile
             11.5.4 Rest of South America
    11.6 Middle East & Africa         
             11.6.1 UAE
             11.6.2 Saudi Arabia
             11.6.3 Qatar
             11.6.4 Iran
             11.6.5 South Africa
             11.6.6 Rest of Middle East & Africa
              
12 Key Developments             
              
13 Company Profiling             
    13.1 Dynavax Technologies          
             13.1.1 Business Overview
             13.1.2 Product/Service Offering
             13.1.3 Financial Overview
             13.1.4 SWOT Analysis
             13.1.5 Key Activities
    13.2 GSK plc         
    13.3 Croda International plc          
    13.4 Seppic         
    13.5 Novavax           
    13.6 SPI Pharma         
    13.7 Agenus Inc         
    13.8 Phibro Animal Health Corporation         
    13.9 Aurorium         
    13.10 Merck KGaA          
    13.11 Hawaii Biotech Inc.         
    13.12 CSL Limited